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Abstract The interplay of psychotic and affective
symptoms is a crucial challenge in understanding the
pathogenesis of psychosis. In this study, we analyzed the
interplay between two subclinical psychosis symptoms
dimensions, and one depression symptoms dimension,
using longitudinal data from Zurich. The Zurich study
started in 1979 with a representative sample of 591 par-
ticipants who were aged 20/21. Follow-up interviews were
conducted at age 23, 28, 30, 35, and 41. The psychiatric
symptoms were assessed with a semi-structured interview
and the SCL 90-R. In this study, we analyzed three
SCL-90-R subscales: the depression symptoms dimension
and two distinct symptoms dimensions of subclinical psy-
chosis, one representing a schizophrenia nuclear symptom
dimension, the other representing a schizotypal symptoms
dimension. Modeling was done with hybrid latent growth
models, thereby including simultaneous and cross-lagged
effects. The interplay between the two subclinical psy-
chosis symptoms dimensions and the depression symptoms
dimension includes several intertwined pathways. The
schizotypal symptoms dimension has strong direct effects
on the schizophrenia nuclear symptoms dimension, but also
on the depression symptoms dimension. The latter has for
its part an effect on the schizophrenia nuclear symptoms
dimension. The main driving force within the dynamic
interplay between depression and psychosis symptoms is a
schizotypal symptoms dimension, which represents social
and interpersonal deficiencies, ideas of reference, suspi-
ciousness, paranoid ideation, and odd behavior. It does not
only directly influence subclinical nuclear schizophrenia
symptoms but also the symptoms of depression.
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Introduction
The interplay between psychotic and affective symptoms is
a crucial challenge in understanding the pathogenesis of
psychosis. In most instances, the prodromal stages of
schizophrenia involve concomitant depressive symptoms
[16–18, 22, 23, 46]. Depression also frequently occurs
during schizophrenic episodes [38]. The stages of depres-
sion and schizophrenia often appear to coalesce [2, 26].
These interactions have left much room for speculation. In
this study, we analyzed the interplay between psychosis
symptoms and depression symptoms using longitudinal
data from the Zurich cohort study which covered a 20-year
period.
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Background
The current concept of schizophrenia is based on Kraepe-
lin’s categorical model of severe mental illnesses [24]. The
Kraepelinian dichotomy between schizophrenia and affec-
tive disorders has received much empirical support and has
formed the respective diagnostic concepts of DSM or ICD.
However, this strict diagnostic dichotomy has been doub-
ted by some scholars. Bleuler [7] in particular observed
the occurrence of depressive symptoms in schizophrenia
to such an extent that he came to regard depression as a
genuine part of the illness process. Ha¨fner et al. [16]
hypothesized that both the depressive and the psychotic
syndrome are preformed reaction patterns of the brain,
though with a different threshold.
To provide more clarity on the interplay between psy-
chosis and depression symptoms in the pathogenesis of psy-
chosis, we should firstly investigate the initial levels of this
interplay, i.e., when the disorder has not yet reached a clinical
level, and secondly analyze the development of this interplay
which is ideally done with longitudinal, prospective data.
Investigating subclinical symptoms
For a long time, research on somatic diseases such as
cancer or cardiovascular diseases has encompassed initial
stages, preclinical processes, and subclinical symptoms.
There is no doubt how important it is to understand the
initial levels of a pathogenetic process, for example in
order to prevent a certain illness. In contrast, it is a long-
standing professional understanding that psychotic symp-
toms are an expression of severe mental illness. Thus, the
current discussion concerning functional psychosis in
general, and schizophrenia, in particular, is impeded by the
fact that most evidence almost exclusively comes from
clinical, most severely ill populations. The related findings
may be biased for several reasons:
• the likelihood of utilizing mental health services
increases with the severity of a disorder; patients with
a less severe illness course usually are not included in
the respective assessments
• most patients involved have already received specific
medication thus distorting the natural course of a
disease entity
• an increasing severity enhances the likelihood of
various comorbid disorders [31] in general, and
substance use in particular, thus also increasing the
chances of confounded and biased findings
• the subclinical onset of the illness is almost inevitably
assessed retrospectively.
We can assess subclinical symptoms in siblings or close
relatives of persons with a clinical expression of a
respective illness, but these symptoms should be ideally
assessed in community samples. In particular, recent work
has suggested that psychosis may be much more frequently
expressed at subclinical levels in community samples than
has been commonly believed [20, 34, 39, 42].
Signifying subclinical syndromes
The subclinical or subthreshold phenotype of psychosis is
often referred to by a diversity of terms as (attenuated)
psychotic experiences or beliefs, psychotic (like) experi-
ences, psychosis proneness, at-risk mental states, schizo-
typy, or schizotaxia [6, 19, 33, 41, 45].
Other authors also have identified those nuclear symp-
toms on a subclinical level. For example Yung et al. [45],
who named those nuclear symptoms ‘‘bizarre experi-
ences’’, derived from a factor analysis of the ‘‘Community
Assessment of Psychotic Experiences’’ (CAPE). Yung and
others regularly regard those subclinical psychotic symp-
toms as transitory to, or prodromes of, frank psychosis.
Persons who develop a full-blown psychosis display the
same symptoms as in the transitory state albeit to a much
greater intensity.
The case is slightly different as regards ‘‘schizotypal
personality disorder’’. Schizotypal personality disorder is
regarded as a chronic constellation and represents in many
regards a clinical endpoint. The APA [1] sees those persons
at no higher risk as the general population for later
development of schizophrenia. Others have highlighted the
usefulness of studying this disorder in promoting insight
into the prodromal state of schizophrenia [36]. Raine [33]
views the schizotypal personality disorder as an attenuated
form of schizophrenia that represents a premorbid or pro-
dromal stage of this major disorder. He hypothesizes two
forms of schizotypal personality disorders: one represents a
relatively stable, neurodevelopmental disorder with sig-
nificant brain and neurocognitive impairments that predis-
pose to schizophrenia, while another form is hypothesized
with a more pronounced psychosocial etiology and more
symptom fluctuation, but no risk for later schizophrenia.
All in all, it seems clear that comparable to other mental
disorders, the expression of psychotic symptoms in a
population is continuous and is characterized by differing
levels of severity and persistence. Thus, psychotic symp-
toms can be studied prospectively, and indeed, long before
the disorder becomes clinically relevant.
Aims of the study
Assessing the interplay between symptoms of psychosis
and depression requires longitudinal data. To date, there
have been only few adequate data sources such as the
Zurich study, a prospective cohort study over a 20-year
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period [3, 28]. The data of the Zurich study include sub-
clinical psychotic symptoms, which previously were
assigned to two psychosis symptoms dimensions (the
schizophrenia nuclear symptoms dimension and the
schizotypal symptoms dimension) [34].
In this study, we used the Zurich study data in order to
examine the interrelations between these psychosis symp-
tom dimensions and depression symptoms. According to
previous research, our prime hypothesis was that depres-
sion symptoms are either a predictor, or a precursor, of
psychotic symptoms.
Methods
Sample
The Zurich study is a prospective longitudinal cohort study.
The Zurich study sample was selected on the basis of a
two-phase procedure as described by Dunn et al. [13],
which is common in epidemiological research. It is char-
acterized by a screening part and an interview part,
whereby the latter is carried out with a subsample of the
initially screened subjects, typically stratified along selec-
ted criteria and cutoffs. In statistical analysis, the stratified
data often need to be weighted for receiving correct point
estimates such as prevalence rates.
The screening procedure in the Zurich study took place
in 1978 with a sample of 4547 subjects (2201 men; 2346
women) born in 1958 and 1959 representative of the canton
of Zurich in Switzerland. At that time, the male partici-
pants were 19 years old (at mandatory conscription) and
the female participants were 20 years old (complete elec-
toral register). In Switzerland, each male citizen has to
present himself for military conscription. With permission
from the authorities and independently of the military
procedure, we could screen randomly half of the con-
scripts. The refusal rate was 0.3%. Women were identified
at the age of 20 by the complete electoral register; half of
the women chosen randomly received mailed question-
naires and 75% of them responded. A lower educational
level was overrepresented among non-responding women;
in order to correct for that the female interview sample was
matched by educational level to the male sample. All
subjects received the Symptom Checklist 90-R (SCL-90-R)
[10], a comprehensive self-report questionnaire of 90
questions, which covers a broad range of psychiatric
symptoms and a demographic questionnaire.
With regard to the second phase, a stratification proce-
dure was applied in order to enrich the interview sample
with cases at risk for the development of psychiatric syn-
dromes. The stratification was based on a cutoff value of
the SCL90-R global severity index (GSI) score. Two-thirds
of the interview sample comprised high scorers (defined by
the 85th percentile or above on the SCL90-R GSI scores),
and one-third of the interview sample were randomly
selected from the rest of the initial sample (GSI scores
below the 85th percentile). A total of 591 subjects (292
men, 299 women) were selected for interview.
Face-to-face interviews were conducted with the inter-
view sample at ages 21, 23, 28, 30, 35, and 41 years. Over
20 years, 62% of the original sample continued to partic-
ipate in the study, and the following proportions partici-
pated in specific numbers of interviews: 47% in all six
interviews; 63% in five interviews; 74% in four interviews;
82% in three interviews; and 91% in at least two inter-
views. On average, about 10% of the participants dropped
out in each interview wave (Fig. 1).Those who dropped out
did not differ significantly from those who stayed in fol-
low-up interviews regarding psychiatrically relevant
demographic characteristics [14]. The analyses reported
below are based on 372 ‘‘stayers’’—participants who
completed five or all six interviews (Fig. 2).
Study instruments
The detailed interviews in the Zurich study were conducted
with the SPIKE (Structured Psychopathological Interview
and Rating of the Social Consequences of Psychological
Disturbances for Epidemiology)—a semi-structured psy-
chopathological interview developed for epidemiological
studies which has been used in all waves since 1979 [3].
The successive SPIKE versions have allowed us to make
diagnoses according to DSM III, IIIR, and IV with the
exception that diagnoses of psychotic disorders could not
be confirmed as the necessary criteria were not included
[4]. SPIKE also recorded data concerning treatment,
Fig. 1 The Zurich study: sample size over six interview waves
Eur Arch Psychiatry Clin Neurosci (2011) 261:11–19 13
123
medication, service use, and impairment in work, social,
and leisure activities.
However, in this study we used only data from the
SCL90-R, which is one of the additional instruments
applied in all interviews. In the SCL90-R, subjects respond
on a five-point Likert scale of distress ranging from ‘‘not at
all’’ (1) at one pole, to ‘‘a little bit’’ (2), ‘‘moderately’’ (3),
‘‘quite a bit’’ (4), and ‘‘extremely’’ (5), at the other. The
time period covered by the SCL90-R in the Zurich study
was 4 weeks. The 90 items of the SCL90-R are grouped
along nine subscales (in the technical parts of the text the
dimensions are labeled as subscales), reflecting a broad
symptom status in a spectrum of individuals ranging from
well controls, to somatic and psychiatric patients. The two
SCL-subscales relevant for psychosis (‘‘paranoid ideation’’
and ‘‘psychoticism’’) were used for analysis. According to
the SCL90-R manual [10], the six-item subscale ‘‘paranoid
ideation’’ is characterized by projective thoughts, hostility,
suspiciousness, grandiosity, centrality, fear of loss of
autonomy, and delusions. The subscale ‘‘psychoticism’’ (10
items) includes items indicative of a withdrawn, isolated,
schizoid lifestyle, as well as items representing symptoms
of psychosis and schizophrenia such as hallucinations and
thought broadcasting. The SCL-90-R depression symptoms
subscale includes 13 items representing depressive moods,
feelings of sadness, loneliness, suicidal thoughts, reduced
(sexual) interest, weakness, weariness, hopelessness, low
self-esteem, and finally, loss of energy.
The SCL90-R has shown good internal consistency and
test–retest reliability [11, 12, 15, 35]. However, the factor
structure of the instrument has shown inconsistent results.
Commonly, less than nine factors are identified [35], and
the psychoticism subscale has been shown to yield the least
consistent results [32]. Such inconsistencies have been
reported since the very first stages of development of
SCL90-R [11].
These inconsistencies led us to challenge the paranoia
and psychoticism subscales of the SCL-90-R and to develop
two new subscales owing to preliminary factor analyses
[34]. The first newly identified schizotypal symptoms sub-
scale matches the original paranoid ideation subscale,
additionally including the items ‘‘feeling lonely even when
with people’’, and ‘‘never feeling close to another person’’.
The second newly identified schizophrenia nuclear symp-
toms subscale includes the items thought insertion, thought
broadcasting, thought control, and hearing voices from the
original psychoticism subscale (Table 1).
Statistical modeling
We used latent growth models (LGMs) [9, 25, 37] to
analyze simultaneously the two distinct psychosis sub-
scales and the depression symptoms subscale. Thus, the
analyses are based on 3*6 data points.
The LGM framework in longitudinal data analysis
allows for modeling in parallel all three longitudinal vari-
ables representing the subscales. In addition, we included
synchronous and time-lagged regression effects between
the longitudinal variables. The respective path analysis
submodels were expected to disentangle in particular the
reciprocal effects between the two psychosis subscales on
the one hand, and the depression symptoms subscale, on
the other. Thus, the two model parts—the latent growth
model and the path analysis submodels—created a hybrid
Fig. 2 The Zurich study:
percentage of participants and
dropouts over six interview
waves
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model, which came close to the more general autoregres-
sive latent trajectories model proposed by Bollen and
Curran [8, 9].
The modeling procedure, which included several steps
as usual in structural equation modeling, is described in the
Appendix (see electronic supplementary material). The
model fit was assessed using the following fit indices
(values in the parentheses follow the suggestions by Yu
[44]): chi-square (P \ 0.01), TLI ([0.95), CFI ([0.96),
SRMR (\0.07), RMSEA (\0.06). In addition, we looked at
the AIC and the BIC. The analyses were carried out with
the Mplus 4.21 software [30]. The missing values were
replaced by the missing value procedure implemented in
Mplus, which assumes missing at random (MAR) data.
Results
The overall trajectories of the schizophrenia nuclear
symptoms subscale, the schizotypal symptoms subscale,
and the depression subscale of the SCL-90-R over 20 years
are shown in Fig. 3. The curves start at age of 20/21 in
1979 and end at age 40/41 in 1999. In all three trajectories,
there is an immediate decline of the scores. The mean and
standard deviation are shown in Fig. 3.
The correlations in each interview between the schizo-
phrenia nuclear symptoms subscale, the schizotypal
symptoms subscale, and the depression subscale of the
SCL-90-R provide a preliminary impression of their
interrelations. They are shown in Table 2. All correlations
are consistently high. However, the correlations between
the schizotypal symptoms and the depression symptoms
subscale are distinctly higher than any correlation includ-
ing schizophrenia nuclear symptoms. The results of sepa-
rate analyses for men and women were perfectly congruent
(results not shown).
The Appendix informs about the results from the sub-
sequent modeling steps in longitudinal data analysis. In a
first intermediate step, we determined a basic trivariate
growth model with all three subscales. This model com-
prised standardized covariances between the latent vari-
ables (representing the initial status and rate of change of
each subscale), and secondly, standardized covariances
between the simultaneous variable scores of each subscale
Table 1 Items of new subscales (schizophrenia nuclear symptoms
subscale and schizotypal symptoms subscale) replacing the paranoia
and psychoticism subscales of the SCL-90-R
SCL-90-R item Original SCL-90-R
subscalea
Schizophrenia nuclear symptoms subscale
7: Someone else can control your thoughts PS
16: Hearing voices other people do not hear PS
35: Other being aware of your thoughts PS
62: Having thoughts that are not your own PS
Schizotypal symptoms subscale
8: Others are to blame for your troubles PN
18: Feeling most people cannot be trusted PN
43: Feeling you are watched by others PN
68: Having ideas, others do not share PN
76: Others not giving you proper credit PN
77: Feeling lonely even when with people PS
83: Feeling people take advantage of you PN
88: Never feeling close to another person PS
PS psychoticism, PN paranoia
a Excluded items (all pertaining to the original psychoticism sub-
scale): 84 Thoughts about sex that bother you a lot, 85 Idea you
should be punished for sins, 87 Idea something is wrong with body,
90 Idea something is wrong with your mind
Fig. 3 Course of the schizophrenia nuclear symptoms subscale, the
schizotypal symptoms subscale and the depression subscale of the
SCL-90-R in the Zurich Study, 1979–1999, i.e., ages 20/21 through
40/41. Note: The standard deviations are 0.54, 0.48, 0.34, 0.36, 0.33,
0.29 (schizophrenia nuclear symptoms subscale); 0.69, 0.63, 0.58,
0.55, 0.56, 0.57 (schizotypal symptoms subscale); 0.71, 0.65, 0.65,
0.62, 0.65, 0.64 (depression subscale)
Table 2 Correlations between the schizophrenia nuclear symptoms
subscale, the schizotypal symptoms subscale, and the depression
subscale of the SCL-90-R, by interview
Interview Nuclear/
depression
Schizotypal/
depression
Nuclear/
schizotypal
1979 0.50 0.77 0.53
1981 0.53 0.77 0.59
1986 0.48 0.77 0.50
1988 0.49 0.76 0.49
1993 0.45 0.75 0.50
1999 0.42 0.76 0.47
All correlations: P \ 0.001
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(see model 1 in the Table A1 from the Appendix of the
supplementary material). Subsequently, we replaced the
standardized covariances one by one by directed paths.
Model 4 (see Table A1 in the Appendix of the supple-
mentary material) had distinctly the best fit when one out of
three possible directed paths between the simultaneous
variable scores was introduced. In this model, depression
scores predict the SNS scores (but not vice versa). Based
on this model, we exchanged also the other standardized
covariances between the simultaneous variable scores with
directed paths. The best model was model 8 (see Table A1
from the Appendix of the supplementary material)
including the following unidirectional effects:
• moderate effect of the depression subscale on the
schizophrenia nuclear symptoms subscale
• moderate effect of the schizotypal symptoms subscale
on the schizophrenia nuclear symptoms subscale
• strong effect of the schizotypal symptoms subscale on
the depression subscale.
The fit of model 8 is comparable to the fit of model 4;
however, model 8 contains distinctly more substantial
information due to the directed paths.
In a final step, we introduced tentatively additional
cross-lagged effects (for example, depression scores at time
t ? 1 regressed on schizotypal symptoms subscale
(schizophrenia nuclear symptoms) scores at time t). The
cross-lagged effects on the schizotypal symptoms sub-
scale—either deriving from the schizophrenia nuclear
symptoms subscale, or the depression subscale—improved
the model fit moderately. This final model is shown in
Fig. 4, the corresponding estimates are reported in Table 3.
The fit indices were chi-square = 159.6 (df 116),
CFI = 0.989, TLI = 0.985, AIC = 5663.7, BIC = 5949.8,
RMSEA = 0.032, SRMR = 0.051.
To summarize, the main driving force within the
dynamics between symptoms of psychosis and depression
is the schizotypal symptoms subscale, which represents
social and interpersonal deficiencies, ideas of reference,
suspiciousness, paranoid ideation, and finally, odd behav-
ior. It exercises a strong effect on the depression symp-
toms, and a moderate effect on the schizophrenia nuclear
symptoms subscale. Depression has partly a mediator
function in this dynamics.
Discussion
This study examined the dynamics of two distinct psy-
chosis symptoms dimensions as previously derived by
means of factor analyses from the SCL 90-R [34], and one
depression symptoms dimension represented by items as
provided by the SCL 90-R manual in a population-based
cohort. Two syndromes represented the psychosis symp-
toms, the first, which we called the nuclear schizophrenia
symptoms dimension, and the second, which was called the
schizotypal symptoms dimension. The schizophrenia
nuclear symptoms (thought insertion, thought broadcasting,
thought control, and hearing voices) correspond to the
Schneiderian first rank symptoms. The second dimension
addresses social and interpersonal deficiencies (‘‘feeling
lonely even when with people’’), with reduced capacity for
close relationships (‘‘never feeling close to another per-
son’’), as well as ideas of reference (‘‘feeling watched by
others’’), odd beliefs (‘‘having ideas that others do not
Fig. 4 Effects in the path model part of the hybrid latent growth
model (see Table 3)
Table 3 The path model part of the hybrid latent growth model:
standardized coefficients over 6 interviews in the Zurich study; ‘‘on’’
represents regression relationships (e.g., schizophrenia nuclear
symptoms regressed on depression)
Effects in
the model
Interviews
At t1 At t2 At t3 At t4 At t5 At t6
1979 1981 1986 1988 1993 1999
SNS on
STS
0.39** 0.42*** 0.25*** 0.23*** 0.28*** 0.32***
SNS on
DEP
0.30** 0.18* 0.22*** 0.23*** 0.21*** 0.15*
DEP on
STS
0.73*** 0.70*** 0.69*** 0.68*** 0.69*** 0.72***
STS on
lag(SNS)
0.04 0.13* 0.09* 0.01 0.11*
STS on
lag(DEP)
0.06 0.12* 0.15** 0.18** 0.07
SNS Schizophrenia nuclear symptoms subscale, STS Schizotypal
symptoms subscale, DEP Depression subscale; all subscales were
derived from the SCL-90-R
* P \ 0.05
** P \ 0.01
*** P \ 0.001
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share’’), suspiciousness (‘‘other people cannot be trusted’’),
or paranoid ideation (‘‘others are to blame for your trou-
bles’’, ‘‘persons are taking advantage of you’’). As such,
this dimension is reminiscent of the criteria required for the
diagnosis of a ‘‘schizotypal personality disorder’’. The
symptoms of our second dimension schizotypal symptoms
also correspond to the positive and negative schizotypal
factors, which were identified by Vollema & Hoijtink [43]
in a three-factor model of schizotypy. Finally, the depres-
sion dimension was calculated according to the SCL-90-R
manual [10]. It includes 13 common symptoms represent-
ing depressive mood, feelings of sadness, loneliness, sui-
cidal thoughts, reduced (sexual) interest, weakness,
weariness, hopelessness, low self-esteem, and loss of
energy.
At first glance, the correlations of all three symptom
dimensions are consistently high over time, but even more
elevated are the correlations between the schizotypal
symptoms, and the depression symptoms. The directions of
the relations and their temporal order emerged in hybrid
latent growth models.
The latent growth models allowed us to examine the
longitudinal data from all three symptom dimensions ‘‘in
parallel’’. Our models indicated that as regards schizo-
typal symptoms, neither the depression symptoms nor the
nuclear symptoms are the main driving force within the
complex triangular relations. The schizotypal symptoms
do not only directly impact on the nuclear symptoms but
clearly also on depression symptoms. There is also a
reverse impact, i.e., from the nuclear schizophrenia
symptom dimension, and from the depression symptom
dimension, on the schizotypal symptoms, but considerably
weaker in strength. Finally, there is also a moderate
impact of the depression syndrome on the nuclear
schizophrenia syndrome. The crucial role of the schizo-
typal symptoms challenges our understanding of how
subclinical psychosis and depression symptoms both
emerge and interact. Thus, depression is not simply a
precursor of subclinical psychosis but is mainly a medi-
ator of schizotypal symptoms, which precede these sub-
clinical nuclear symptoms.
Disentangling the hybrid latent growth model
The ‘‘latent growth’’ part of the hybrid model accounted for
the longitudinal effects in the data. All three syndromes
showed a decline over time, which is due to the regression
to the mean, i.e., a statistical phenomenon. But the decline
might also express the natural course of these symptom
dimensions as in particular in schizophrenia, there is a
similar decline with the highest rates in young adulthood.
The other part of the hybrid model, which involves path
analysis, comprised simultaneous and lagged paths. These
effects were selected after comparison of alternative
models at each step of the analysis.
It is noteworthy that the path analytic model tells us that
the impact of the schizotypal symptoms on schizophrenia
nuclear symptoms includes two pathways, a direct one and
an indirect one via depressive symptoms. The direct (and in
our study, weaker) pathway from schizotypal symptoms to
schizophrenia nuclear symptoms reflects the same pathway
as from schizotypy to schizophrenia. On a subclinical level,
the pathway identified in this study supports the hypothesis
of Raine [33] that there might be a form of schizotypy with a
more pronounced psychosocial etiology, and more symp-
tom fluctuation. Our dimension ‘‘schizotypal symptoms’’ is
highly variable in the symptom course over time and shows
a strong link to childhood adversity as a risk factor [34].
The link with depression symptoms
The other challenge emerging from this study concerns the
link with depression. Numerous studies have documented
the association between depression and psychotic symp-
toms. Our model suggests that the major part of the asso-
ciations with schizophrenia nuclear symptoms is
introduced by shared variance due to the impact of the
schizotypal symptoms. There is only a minor direct effect
of the depression symptom dimension on the nuclear
symptoms. Thus, some hypotheses and theories in this
direction possibly need to be re-examined. For example,
our results do not strongly support the empirical findings
and further hypotheses of Ha¨fner and colleagues [17, 27]
that due to a low threshold, depressive symptoms are
widespread in the population and independent of frank
psychosis with a significant higher threshold. Our findings
propose suggest strongly that schizotypal symptoms pref-
erably convey depression symptoms, which for their part
can convey schizophrenia nuclear symptoms. A congruent
view was proposed by Kirkpatrick and colleagues [21, 29].
They found that suspiciousness, which is an acknowledged
symptom of schizotypy, is a risk factor for major depres-
sion in schizophrenia.
Thus, not only the mechanisms endorsing psychosis
symptoms need a closer look, but also the depression
symptoms themselves are deserving of closer scrutiny. Our
models confirmed that the effect of the schizotypal symp-
toms on depression is much more relevant than it is on the
reciprocal effect. Schizotypal symptoms even appear to be
a major force influencing depression. The strong impact of
schizotypal symptoms on depression might be also inter-
preted as a depressive reaction to the experience of being
excluded and lonely, as many persons suffering from
schizotypal symptoms describe it.
To summarize, schizotypy, depression, and schizophre-
nia nuclear symptoms—the latter ones being assumed to
Eur Arch Psychiatry Clin Neurosci (2011) 261:11–19 17
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build the core of schizophrenia—interact on a subclinical
level, paving the pathway to clinical psychosis. The model
presented in this study improves our understanding of the
dynamics in the development of psychosis on a sub-
threshold level. Many well-known findings may be inte-
grated in this model, thus leading to new perspectives.
Limitations
Despite its strengths, our study also has its limitations. This
study entailed only a part of the syndromes representing
psychosis, namely positive (nuclear) symptoms. Negative
symptoms, such as disorganization, and putative other
dimensions of psychosis are not covered by the SCL-90-R
or other data in the Zurich study. There is no corresponding
psychosis section in the SPIKE questionnaire, which might
serve to control or supplement the information derived
from the SCL-90-R. The SCL-90-R also underestimates the
prevalence of symptoms, which is commonly described by
a 12-month period. The symptoms assessed by the SCL-90-
R in the Zurich study only cover the last 4 weeks. From a
methodological point of view, one should be aware that the
time periods between the interviews of the Zurich study are
up to 5 years. Thus, our analysis could assess only partially
the dynamics between the syndromes. Shorter time periods
between the interviews doubtless would provide stronger
lagged effects. And finally the models represent a dimen-
sion-guided approach to the data. Thus, the results would
be valid for the most frequent or most typical patterns.
Nevertheless, there are many cases not compatible with the
typical patterns: for instance, persons with high levels on
only one of the dimensions, or persons with a reversed
development, i.e., for example who developed nuclear
symptoms first, and only later, schizotypal symptoms.
Cluster analysis within a subgroup-guided approach [5, 40]
remains to be conducted as a next step in order to describe
not only the most typical patterns but also subgroups with
less frequent patterns.
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